Intravenous Tislelizumab

DRUG2 trials

Sponsors

Zhonglin Hao, BeOne Medicines

Conditions

Esophageal CancerEsophagogastric Junction CancerGastroesophageal Junction AdenocarcinomaMetastatic Gastric Adenocarcinoma

Phase 2

ChemoRadiation And Tislelizumab for Esophageal/EGJ Cancer

WithdrawnNCT05245760

Zhonglin HaoEsophageal Cancer, Esophagogastric Junction Cancer

Start: 2022-04-30End: 2033-12-31Updated: 2022-11-08

Phase 3

A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus Intravenous Infusion Plus Chemotherapy in Patients With Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

RecruitingNCT07043400

BeOne MedicinesGastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma

Start: 2025-08-27End: 2028-04-22Target: 351Updated: 2026-03-19